Stratification model based on early postprostatectomy prostate-specific antigen kinetics may help to reduce the risk of overtreatment in candidates for adjuvant radiotherapy

References

• Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, et al. European Organisation For Research and Treatment of Cancer, Radiation Oncology and Genito-Urinary Groups. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012;380:2018–27.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009;181:956–62.
   PubMed Web of Science ®Google Scholar
• Abdollah F, Suardi N, Cozzarini C, Gallina A, Capitanio U, Bianchi M, et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 2013;63:998–1008.
   PubMed Web of Science ®Google Scholar
• Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001;165:119–25.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline. J Urol 2013;190:441–9.
   PubMed Web of Science ®Google Scholar
• Eisenberg MS, Karnes RJ, Kaushik D, Rangel L, Bergstralh EJ, Boorjian SA. Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy. J Urol 2013;190:1735–41.
   PubMed Web of Science ®Google Scholar
• Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, Stöckle M, et al. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial. Int J Radiat Oncol Biol Phys 2015;91:288–94.
   PubMed Web of Science ®Google Scholar
• Kowalczyk KJ, Gu X, Nguyen PL, Lipsitz SR, Trinh QD, Lynch JH, et al. Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer. Urol Oncol 2014;32:303–8.
   PubMed Web of Science ®Google Scholar
• King CR. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys 2012;84:104–11.
   PubMed Web of Science ®Google Scholar
• Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909–16.
   PubMed Web of Science ®Google Scholar
• Lotan Y, Roehrborn CG. Clearance rates of total prostate specific antigen (PSA) after radical prostatectomy in African-Americans and Caucasians. Prostate Cancer Prostatic Dis 2002;5:111–14.
   PubMed Web of Science ®Google Scholar
• Morgan TM, Meng MV, Cooperberg MR, Cowan JE, Weinberg V, Carroll PR, et al. A risk-adjusted definition of biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis 2014;17:174–9.
   PubMed Web of Science ®Google Scholar
• Mir MC, Li J, Klink JC, Kattan MW, Klein EA, Stephenson AJ. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. Eur Urol 2014;66:204–10.
   PubMed Web of Science ®Google Scholar
• DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45.
   PubMed Web of Science ®Google Scholar
• Rouanne M, Rode J, Campeggi A, Allory Y, Vordos D, Hoznek A, et al. Long-term impact of positive surgical margins on biochemical recurrence after radical prostatectomy: ten years of follow-up. Scand J Urol 2014;48:131–7.
   PubMed Web of Science ®Google Scholar
• Shi Z, Pinnock CB, Kinsey-Trotman S. Prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer death. Radiother Oncol 2013;107:129–33.
   PubMed Web of Science ®Google Scholar
• Lo EN, Beckett LA, Pan CX, Robles D, Suga JM, Sands JM, et al. Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients. Prostate Cancer Prostatic Dis 2015;18:144–8.
   PubMed Web of Science ®Google Scholar
• Servoll E, Sæter T, Vlatkovic L, Nesland JM, Waaler G, Axcrona K. Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience. Scand J Urol 2015;49:218–23.
   PubMed Web of Science ®Google Scholar
• Audenet F, Seringe E, Drouin SJ, Comperat E, Cussenot O, Bitker MO, Rouprêt M. Persistently elevated prostate-specific antigen at six weeks after radical prostatectomy helps in early identification of patients who are likely to recur. World J Urol 2012;30:239–44.
   PubMed Web of Science ®Google Scholar
• Eisenberg ML, Davies BJ, Cooperberg MR, Cowan JE, Carroll PR. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol 2010;57:622–9.
   PubMed Web of Science ®Google Scholar
• Shen S, Lepor H, Yaffee R, Taneja SS. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol 2005;173:777–80.
   PubMed Web of Science ®Google Scholar
• Moreira DM, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, et al. Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases. Int J Urol 2010;17:914–22.
   PubMed Web of Science ®Google Scholar
• Simon RM, Howard L, Freedland SJ, Aronson WJ, Terris MK, Kane CJ, et al. Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted? BJU Int 2016;117:897–903.
   PubMed Web of Science ®Google Scholar